NEW YORK (TheStreet) -- Shares of Becton Dickinson (BDX - Get Report) are declining in afternoon trading today as the Franklin Lakes, NJ-based medical technology company reported better-than-expected second quarter earnings, but lowered its full-year revenue guidance.
Before today's opening bell, Becton Dickinson posted adjusted earnings of $2.35 per share, surpassing Wall Street's estimated $2.21 per share. Revenue came in at $3.2 billion, falling just short of analysts projected $3.21 billion.
During the 2015 second quarter, the company reported earnings of $2.05 per share on revenue of $3.13 billion.
Becton Dickinson now expects its 2016 revenues to increase 21% to 21.5%, down from its prior estimates of 21.5% to 22%. Adjusted earnings are projected to be in the range of $8.50 per share and $8.57 per share, while Wall Street expects full-year earnings of $8.55 per share.
The company added that it reported strong performance in its Medication Management Solutions and Diabetes Care Units. Its Pharmaceutical Systems and Respiratory Solutions units were negatively impacted by customer ordering patterns and timing of capital projects.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:
We rate BECTON DICKINSON & CO as a Buy with a ratings score of A-. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
You can view the full analysis from the report here: BDX